Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(Use as many sheets as necessary)*				Application Number	09/432,503
				Filing Date	November 2, 1999
				First Named Inventor	Cech, Thomas R.
				Art Unit	1635
				Examiner Name	Jon E. Angell
Sheet	1	of	3	Attorney Docket Number	015389-002611US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US 6,120,764	09-19-2000	Graham et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

61318320

Substitute for form 1449B/PTO	**Complete if Known**	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	09/432,503
	Filing Date	November 2, 1999
	First Named Inventor	Cech, Thomas R.
	Art Unit	1635
(Use as many sheets as necessary)	Examiner Name	Jon E. Angell
Sheet	2	of	3	Attorney Docket Number	015389-002611US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	2	BACHAND, F. & AUTEXIER, C., "Functional regions of human telomerase reverse transcriptase and human telomerase RNA required for telomerase activity and RNA-protein interactions," *Mol. Cell. Biol. 21*:1888-97 (2001).	☐
	3	BRYAN, T. et al., "A mutant of *Tetrahymena* telomerase reverse transcriptase with increased processivity," *J. Biol. Chem. 275*:24199-207 (2000).	☐
	4	BRYAN, T. et al., "Telomerase reverse transcriptase genes identified in *Tetrahymena thermophilia* and *Oxytricha trifallax*," *Proc. Natl. Acad. Sci. USA 95*:8479-84 (1998).	☐
	5	BRYAN, T. et al., "Telomerase RNA bound by protein motifs specific to telomerase reverse transcriptase," *Molec. Cell 6*:493-99 (2000).	☐
	6	COLGIN, L. et al., "The hTERTα splice variant is a dominant negative inhibitor of telomerase activity," *Neoplasia 2*(5):426-32 (2000).	☐
	7	EMBL Database entry Greenberg et al., AF051911, XP002091313 (April 6, 1998).	☐
	8	EMBL Database entry Martin-Rivera et al., AF073311, XP002091314 (September 9, 1998).	☐
	9	FARMERY, M. & BULLEID, N., "Major histocompatibility class I folding, assembly, and degradation: A paradigm for two-stage quality control in the endoplasmic reticulum," *Prog. Nucl. Acid Res. Mol. Biol. 67*:235-68 (2001).	☐
	10	FRIEDMAN, K. et al., "Essential functions of amino-terminal domains in the yeast telomerase catalytic subunit revealed by selection for variable mutants," *Genes Dev. 13*(21):2863-74 (1999).	☐
	11	HAERING, C. et al., "Analysis of telomerase catalytic subunit mutants *in vivo* and *in vitro* in *Schizosaccharomyces pombe*," *Proc. Natl. Acad. Sci. USA 97*:6367-72 (2000).	☐
	12	HAHN, W. et al., "Inhibition of telomerase limits the growth of human cancer cells," *Nature Med. 5*:1164-70 (1999).	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(Use as many sheets as necessary)*	Application Number	09/432,503
	Filing Date	November 2, 1999
	First Named Inventor	Cech, Thomas R.
	Art Unit	1635
	Examiner Name	Jon E. Angell
Sheet 3 of 3	Attorney Docket Number	015389-002611US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	13	LAI, C. et al., "RNA binding domain of telomerase reverse transcriptase," *Mol. Cell. Biol.* *21*:990-1000 (2001).	☐
	14	LEEM et al., "The human telomerase gene: complete genomic sequence and analysis of tandem repeat polymorphisms in intronic regions," *Oncogene 21*:769-77 (2002).	☐
	15	LI, H. et al., "Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells," *J. Biol. Chem. 272*:16729-32 (1997).	☐
	16	MEYERS, R., Ed., <u>Molecular Biology and Biotechnology, A Comprehensive Desk Reference</u>, Wiley-VCH, New York, p. 187 (1995).	☐
	17	PEREZ, H. et al., "Human formyl peptide receptor ligand binding domain(s). Studies using an improved mutagenesis/expression vector reveal a novel mechanism for the regulation of receptor occupancy," *J. Biol. Chem. 269*(36):22485-7 (1994).	☐
	18	SOLHEIM, J., "Class I MHC molecules: Assembly and antigen presentation," *Immunol. Rev. 172*:11-19 (1999).	☐
	19	XIA, J. et al., "Identification of functionally important domains in the N-terminal region of telomerase reverse transcriptase," *Mol. Cell. Biol. 20*:5196-207 (2000).	☐
	20	ZAKHAROVA, O. et al., "Structural constraints in the HIV-1 reverse transcriptase-primer/template complex for the initiation of DNA synthesis from primer tRNA^{Lys3}," *Biochem. 37*:13343-8 (1998).	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.